Janssen Pharmaceutical

Data Shows TREMFYA Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years

SPRING HOUSE, PA — The Janssen Pharmaceutical Companies of Johnson & Johnson announced recent comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis …

Data Shows TREMFYA Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years Read More